Lakefront Biotherapeutics (GLPGF) Net Income (QoQ) (2016 - 2026)
Powered by 
Analysis
Lakefront Biotherapeutics (GLPGF) Net Income (QoQ) (2016 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 211.50 Bn | 197.51 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 181.29 Bn | 178.11 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 132.16 Bn | 124.30 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 82.55 Bn | 74.56 Bn | 3.93 Bn |
| 5 | Argenx Se | 61.65 Bn | 56.47 Bn | 1.37 Bn |
| 6 | Moderna | 54.65 Bn | 49.52 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 34.18 Bn | 30.87 Bn | 992.69 Mn |
| 8 | Biogen | 31.36 Bn | 30.07 Bn | 1.96 Bn |
| 9 | Roivant Sciences | 30.01 Bn | 30.01 Bn | 1.16 Mn |
| 10 | Lakefront Biotherapeutics | 1.73 Bn | 1.73 Bn | 3.51 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -392.95% |
| Mar 31, 2026 | -99.99% |
| Dec 31, 2025 | 56,864.13% |
| Sep 30, 2025 | -430.79% |
| Jun 30, 2025 | 206.64% |
| Mar 31, 2025 | -100.21% |
| Dec 31, 2024 | 72,614.88% |
| Sep 30, 2024 | -285.82% |
| Jun 30, 2024 | -40.81% |
| Mar 31, 2024 | -98.44% |
| Dec 31, 2023 | 17,701.38% |
| Sep 30, 2023 | -5,681.25% |
| Jun 30, 2023 | -97.42% |
| Mar 31, 2023 | 111.02% |
| Dec 31, 2022 | -498.96% |
| Sep 30, 2022 | 53.96% |
| Jun 30, 2022 | -628.61% |
| Mar 31, 2022 | 90.63% |
| Dec 31, 2021 | 34.89% |
| Sep 30, 2021 | -134.12% |